NOV 28, 2016 11:07 AM PST

Cancer Drug May be Repurposed to Treat Muscular Dystrophy

WRITTEN BY: Xuan Pham
A cancer drug that’s approved for the treatment of kidney cancer may also be effective against a form of muscular dystrophy.
 

Sunitinib is a small-molecule drug that inhibits receptor tyrosine kinases (RTK). It was approved by the FDA for the treatment of renal cell carcinoma and a form of gastrointestinal tumor in 2006. Now, researchers at the King’s College London say the mechanism behind this drug may also act to improve muscle strength in patients with facioscapulohumeral dystrophy (FSHD).
 
FSHD is a genetically inherited form of muscular dystrophy that primarily affects the muscles around the face, shoulders, and upper arms. Patients with this condition experience progressive muscle wasting that starts in early childhood. The muscle weakness can severely impair mobility, speaking, and even breathing.
 
"Muscle dystrophies are an untreatable collection of diseases that result in progressive loss of mobility and often premature death, and affect millions of people worldwide,” said Robert Knight, Principal Investigator at the Division of Craniofacial Development and Stem Cell Biology at King’s College London’s Dental Institute, and the study’s co-lead author.
 
In studying muscle biology, researchers noted that a receptor tyrosine kinase Rearranged during transfection (RET) seemed to be upregulated in muscle stem cells that express the DUX4 protein. In FSHD, the genomic region controlling DUX4 appears to be abnormally activated (due to hypomethylation). This, in turn, overstimulates the production and activity of DUX4, which seems to contribute to the muscle weakness characteristic of FSHD.
 
Could an RTK inhibitor reverse this effect? This was the researcher’s main hypothesis, and they tested it first by confirming that overexpression of DUX4 in mice led to upregulation of RET. Furthermore, administration of sunitinib, an RTK inhibitor, suppressed RET activity and reduced damage to muscle cells.
 

“Specifically, blocking DUX4-mediated RET signaling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting RET signaling as potential drug target," the authors explain.
 
The drug shows promise in improving muscle strength for patients afflicted with FSHD. And since the drug is already approved, repurposing it for the treatment of FSHD may take much less time, assuming further studies also find the same promising results.
 
“The discovery that an approved anticancer treatment may prove useful for enhancing the ability of stem cells to repair muscle in a type of muscle dystrophy affecting face and shoulder muscles offers a new route for putative therapies for many patients,” said Knight.

Additional sources: King's College London press release, MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 06, 2018
Cell & Molecular Biology
JUN 06, 2018
New Role for Protein Complex Provides Insight Into Cancer Development
Researchers found that RSC plays an important role in chromosome distribution....
JUN 16, 2018
Cancer
JUN 16, 2018
Lung Cancer Rates Increasing in White and Hispanic Young Women
Lung cancer has long been tied to smoking and had a higher incidence in men than women. A new study shows rates of lung cancer are increasing in some groups of young women....
JUN 26, 2018
Cancer
JUN 26, 2018
Five "-omics" Fields Introduced
An introduction to genomics, transcriptomics, proteomics, epigenomics, and metabolomics....
JUL 10, 2018
Cancer
JUL 10, 2018
TdT Positive Cells - Not Just for Neoplasms
TdT positive cells are associated with early lymphoid neoplasms but healthy lymphoid precursors can also be positive, especially in pediatric patient lymph nodes....
JUL 17, 2018
Health & Medicine
JUL 17, 2018
Can the Keto Diet Make Cancer Treatment More Effective?
It’s been said that “you are what you eat” but with so many diet plans and trends, it can be hard to choose. Paleo, keto, Mediterranean,...
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
Loading Comments...